Mike Supreme

ALT Slide 1 of 5 of a Medicenna science explainer. Label: "The basics." Headline: "Meet IL-2, your immune system's accelerator." Illustration: an orange sphere labelled "IL-2, the accelerator" moves toward a large light-blue immune cell with receptors on its surface. Tags: "grow," "survive" and "respond." Text: "IL-2 is a natural messenger protein. It helps immune cells grow, survive, and respond."

ALT Slide 2 of 5. Label: "A little history." Headline: "One of the first cancer immunotherapies." Three cards on a dark purple background: "Approved: for kidney cancer and melanoma." Then "But": "Not selective: it can activate cancer-fighting cells, but also regulatory T cells that restrain immune responses." And "Short-lived and toxic: it doesn't last long in the body and has more safety concerns." Text: "IL-2 was one of the first immunotherapies approved for kidney cancer and melanoma. But it was hard to use."

ALT Slide 3 of 5. Label: "The redesign." Headline: "Medicenna re-engineered it." Illustration: purple spheres, each joined to a pale lavender oval, move toward a large light-blue cell and dock onto receptors on its surface. A pointer labels one "MDNA11, an engineered IL-2." Two similar cells sit behind the first, with tags "activated" and "multiplying." Cell label: "CD8+ T cells and NK cells, immune cells that can attack cancer." Text: "MDNA11 is engineered IL-2, designed to favour CD8+ T cells and NK cells over regulatory T cells." Footer: "MDNA11 is investigational."

ALT Slide 4 of 5. Label: "Built to last." Headline: "And made it last longer." Two cards. Left, "Traditional IL-2 therapy": an orange sphere above an hourglass whose sand has nearly run out, labelled "short-lived, dosed every 8 hours." Right, "MDNA11, engineered IL-2 + albumin": a purple sphere joined to a pale lavender oval above an hourglass that is still mostly full, labelled "lasts longer, dosed every 14 days." Text: "MDNA11's engineered IL-2 is joined to albumin, a natural blood protein, to help it last longer in the body. The goal: less frequent dosing than traditional IL-2 therapy, with fewer side effects." Footer: "MDNA11 is investigational."

ALT Medicenna graphic labelled "Autoimmune disease, new preclinical data today." Headline: "One Target. Two Pathways." Text: "MDNA209 is designed to block CD122 and inhibit IL-2 and IL-15." Friday, October 23, 4:30 p.m. CEST, at The Promises of Treg and Interleukin-2 Therapies, Paris. Presenter: Dr. Minh D. To. TSX: MDNA | OTCQB: MDNAF. The background is a 3D render of purple protein clusters.